A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Orano Med LLC
Eli Lilly and Company
Accent Therapeutics
National Institutes of Health Clinical Center (CC)
Pheon Therapeutics
Novartis
Elicio Therapeutics
GONGCHU Biotechnology Co., Ltd
Novita Pharmaceuticals, Inc.
Compugen Ltd
Black Diamond Therapeutics, Inc.
Compugen Ltd
ADC Therapeutics S.A.
Ohio State University Comprehensive Cancer Center
MacroGenics
MacroGenics
Novartis
Abramson Cancer Center at Penn Medicine
University of Maryland, Baltimore
Masonic Cancer Center, University of Minnesota
AbbVie
National Institutes of Health Clinical Center (CC)
AbbVie
Altor BioScience
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
City of Hope Medical Center
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
CritiTech, Inc.
Calando Pharmaceuticals
National Cancer Institute (NCI)
Altor BioScience
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Eisai Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Cancer Research UK
Roger Williams Medical Center